Anticancer activity of Schiff base–Poloxamer P85 combination against kidney cancer
Purpose Renal cell carcinoma (RCC) accounts for approximately 80% of the primary renal cancers, and current treatment strategies are not sufficient to provide a certain solution. Since there are not many treatment options, interest in discovery of alternative drugs has increased. Methods In the curr...
Gespeichert in:
| Veröffentlicht in: | International urology and nephrology 2018-02, Vol.50 (2), p.247-255 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 255 |
|---|---|
| container_issue | 2 |
| container_start_page | 247 |
| container_title | International urology and nephrology |
| container_volume | 50 |
| creator | Doğan, Ayşegül Demirci, Selami Telci, Dilek Canikyan, Serli Kongur, Merve Dede, Bülent Şahin, Fikrettin |
| description | Purpose
Renal cell carcinoma (RCC) accounts for approximately 80% of the primary renal cancers, and current treatment strategies are not sufficient to provide a certain solution. Since there are not many treatment options, interest in discovery of alternative drugs has increased.
Methods
In the current study, anticancer activity of a novel heterodinuclear Cu(II)–Mn(II) complex (Schiff base—SB) in combination with poly(ethylene oxide) and poly(propylene oxide) block copolymer (pluronic) P85 was tested against RCC. Cell viability, apoptosis and gene expression analysis were conducted in vitro by using Renca cells.
Results
The results revealed that the SB–P85 combination decreased cell proliferation by increasing the apoptotic gene expressions and apoptosis. Renca-injected BALB/c mice were used to mimic early stage of RCC model. Treatment with SB–P85 combination suppressed tumor formation and growth compared to baseline.
Conclusion
Overall, SB–P85 showed promising anticancer activity against RCC in vitro and in vivo. |
| doi_str_mv | 10.1007/s11255-017-1782-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1982840810</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1981999934</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-8894e1be6d1d1088ea3bf715878fe83cd31d51651d858d81f279f62590bae3353</originalsourceid><addsrcrecordid>eNp1kM9O3DAQh62qCJY_D9ALitQLlxSPHSfjI0KFIiGxUuFsOY4N3m5siBPUvfEOfUOepF6FoqpS5zKH-eY3o4-QT0C_AKXNaQJgQpQUmhIaZKX8QBYgGl4ygdVHsqCcQgk143tkP6UVpVQipbtkj0mGWEG9ILdnYfRGB2OHQpvRP_txU0RXfDcP3rmi1cm-vvxaxnX8qfvMLFEUJvatD3r0MRT6XvuQxuKH74LdFHPSIdlxep3s0Vs_IHcXX2_Pv5XXN5dX52fXpeENG0tEWVlobd1BBxTRat66BgQ26Cxy03HoBNQCOhTYITjWSFczIWmrLeeCH5CTOfdxiE-TTaPqfTJ2vdbBxikpkMiwogg0o5__QVdxGkL-bkuBzMWrTMFMmSGmNFinHgff62GjgKqtcjUrV1m52ipXMu8cvyVPbW-7940_jjPAZiDlUbi3w1-n_5v6G76Ri2Y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1981999934</pqid></control><display><type>article</type><title>Anticancer activity of Schiff base–Poloxamer P85 combination against kidney cancer</title><source>SpringerLink Journals</source><creator>Doğan, Ayşegül ; Demirci, Selami ; Telci, Dilek ; Canikyan, Serli ; Kongur, Merve ; Dede, Bülent ; Şahin, Fikrettin</creator><creatorcontrib>Doğan, Ayşegül ; Demirci, Selami ; Telci, Dilek ; Canikyan, Serli ; Kongur, Merve ; Dede, Bülent ; Şahin, Fikrettin</creatorcontrib><description>Purpose
Renal cell carcinoma (RCC) accounts for approximately 80% of the primary renal cancers, and current treatment strategies are not sufficient to provide a certain solution. Since there are not many treatment options, interest in discovery of alternative drugs has increased.
Methods
In the current study, anticancer activity of a novel heterodinuclear Cu(II)–Mn(II) complex (Schiff base—SB) in combination with poly(ethylene oxide) and poly(propylene oxide) block copolymer (pluronic) P85 was tested against RCC. Cell viability, apoptosis and gene expression analysis were conducted in vitro by using Renca cells.
Results
The results revealed that the SB–P85 combination decreased cell proliferation by increasing the apoptotic gene expressions and apoptosis. Renca-injected BALB/c mice were used to mimic early stage of RCC model. Treatment with SB–P85 combination suppressed tumor formation and growth compared to baseline.
Conclusion
Overall, SB–P85 showed promising anticancer activity against RCC in vitro and in vivo.</description><identifier>ISSN: 0301-1623</identifier><identifier>EISSN: 1573-2584</identifier><identifier>DOI: 10.1007/s11255-017-1782-9</identifier><identifier>PMID: 29288416</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Antitumor activity ; Apoptosis ; Cell proliferation ; Drug discovery ; Gene expression ; Kidney cancer ; Medicine ; Medicine & Public Health ; Nephrology ; Polyethylene oxide ; Propylene oxide ; Renal cell carcinoma ; Urology ; Urology - Original Paper</subject><ispartof>International urology and nephrology, 2018-02, Vol.50 (2), p.247-255</ispartof><rights>Springer Science+Business Media B.V., part of Springer Nature 2017</rights><rights>International Urology and Nephrology is a copyright of Springer, (2017). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-8894e1be6d1d1088ea3bf715878fe83cd31d51651d858d81f279f62590bae3353</citedby><cites>FETCH-LOGICAL-c372t-8894e1be6d1d1088ea3bf715878fe83cd31d51651d858d81f279f62590bae3353</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11255-017-1782-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11255-017-1782-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29288416$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Doğan, Ayşegül</creatorcontrib><creatorcontrib>Demirci, Selami</creatorcontrib><creatorcontrib>Telci, Dilek</creatorcontrib><creatorcontrib>Canikyan, Serli</creatorcontrib><creatorcontrib>Kongur, Merve</creatorcontrib><creatorcontrib>Dede, Bülent</creatorcontrib><creatorcontrib>Şahin, Fikrettin</creatorcontrib><title>Anticancer activity of Schiff base–Poloxamer P85 combination against kidney cancer</title><title>International urology and nephrology</title><addtitle>Int Urol Nephrol</addtitle><addtitle>Int Urol Nephrol</addtitle><description>Purpose
Renal cell carcinoma (RCC) accounts for approximately 80% of the primary renal cancers, and current treatment strategies are not sufficient to provide a certain solution. Since there are not many treatment options, interest in discovery of alternative drugs has increased.
Methods
In the current study, anticancer activity of a novel heterodinuclear Cu(II)–Mn(II) complex (Schiff base—SB) in combination with poly(ethylene oxide) and poly(propylene oxide) block copolymer (pluronic) P85 was tested against RCC. Cell viability, apoptosis and gene expression analysis were conducted in vitro by using Renca cells.
Results
The results revealed that the SB–P85 combination decreased cell proliferation by increasing the apoptotic gene expressions and apoptosis. Renca-injected BALB/c mice were used to mimic early stage of RCC model. Treatment with SB–P85 combination suppressed tumor formation and growth compared to baseline.
Conclusion
Overall, SB–P85 showed promising anticancer activity against RCC in vitro and in vivo.</description><subject>Antitumor activity</subject><subject>Apoptosis</subject><subject>Cell proliferation</subject><subject>Drug discovery</subject><subject>Gene expression</subject><subject>Kidney cancer</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Nephrology</subject><subject>Polyethylene oxide</subject><subject>Propylene oxide</subject><subject>Renal cell carcinoma</subject><subject>Urology</subject><subject>Urology - Original Paper</subject><issn>0301-1623</issn><issn>1573-2584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNp1kM9O3DAQh62qCJY_D9ALitQLlxSPHSfjI0KFIiGxUuFsOY4N3m5siBPUvfEOfUOepF6FoqpS5zKH-eY3o4-QT0C_AKXNaQJgQpQUmhIaZKX8QBYgGl4ygdVHsqCcQgk143tkP6UVpVQipbtkj0mGWEG9ILdnYfRGB2OHQpvRP_txU0RXfDcP3rmi1cm-vvxaxnX8qfvMLFEUJvatD3r0MRT6XvuQxuKH74LdFHPSIdlxep3s0Vs_IHcXX2_Pv5XXN5dX52fXpeENG0tEWVlobd1BBxTRat66BgQ26Cxy03HoBNQCOhTYITjWSFczIWmrLeeCH5CTOfdxiE-TTaPqfTJ2vdbBxikpkMiwogg0o5__QVdxGkL-bkuBzMWrTMFMmSGmNFinHgff62GjgKqtcjUrV1m52ipXMu8cvyVPbW-7940_jjPAZiDlUbi3w1-n_5v6G76Ri2Y</recordid><startdate>20180201</startdate><enddate>20180201</enddate><creator>Doğan, Ayşegül</creator><creator>Demirci, Selami</creator><creator>Telci, Dilek</creator><creator>Canikyan, Serli</creator><creator>Kongur, Merve</creator><creator>Dede, Bülent</creator><creator>Şahin, Fikrettin</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20180201</creationdate><title>Anticancer activity of Schiff base–Poloxamer P85 combination against kidney cancer</title><author>Doğan, Ayşegül ; Demirci, Selami ; Telci, Dilek ; Canikyan, Serli ; Kongur, Merve ; Dede, Bülent ; Şahin, Fikrettin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-8894e1be6d1d1088ea3bf715878fe83cd31d51651d858d81f279f62590bae3353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Antitumor activity</topic><topic>Apoptosis</topic><topic>Cell proliferation</topic><topic>Drug discovery</topic><topic>Gene expression</topic><topic>Kidney cancer</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Nephrology</topic><topic>Polyethylene oxide</topic><topic>Propylene oxide</topic><topic>Renal cell carcinoma</topic><topic>Urology</topic><topic>Urology - Original Paper</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Doğan, Ayşegül</creatorcontrib><creatorcontrib>Demirci, Selami</creatorcontrib><creatorcontrib>Telci, Dilek</creatorcontrib><creatorcontrib>Canikyan, Serli</creatorcontrib><creatorcontrib>Kongur, Merve</creatorcontrib><creatorcontrib>Dede, Bülent</creatorcontrib><creatorcontrib>Şahin, Fikrettin</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>International urology and nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Doğan, Ayşegül</au><au>Demirci, Selami</au><au>Telci, Dilek</au><au>Canikyan, Serli</au><au>Kongur, Merve</au><au>Dede, Bülent</au><au>Şahin, Fikrettin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anticancer activity of Schiff base–Poloxamer P85 combination against kidney cancer</atitle><jtitle>International urology and nephrology</jtitle><stitle>Int Urol Nephrol</stitle><addtitle>Int Urol Nephrol</addtitle><date>2018-02-01</date><risdate>2018</risdate><volume>50</volume><issue>2</issue><spage>247</spage><epage>255</epage><pages>247-255</pages><issn>0301-1623</issn><eissn>1573-2584</eissn><abstract>Purpose
Renal cell carcinoma (RCC) accounts for approximately 80% of the primary renal cancers, and current treatment strategies are not sufficient to provide a certain solution. Since there are not many treatment options, interest in discovery of alternative drugs has increased.
Methods
In the current study, anticancer activity of a novel heterodinuclear Cu(II)–Mn(II) complex (Schiff base—SB) in combination with poly(ethylene oxide) and poly(propylene oxide) block copolymer (pluronic) P85 was tested against RCC. Cell viability, apoptosis and gene expression analysis were conducted in vitro by using Renca cells.
Results
The results revealed that the SB–P85 combination decreased cell proliferation by increasing the apoptotic gene expressions and apoptosis. Renca-injected BALB/c mice were used to mimic early stage of RCC model. Treatment with SB–P85 combination suppressed tumor formation and growth compared to baseline.
Conclusion
Overall, SB–P85 showed promising anticancer activity against RCC in vitro and in vivo.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>29288416</pmid><doi>10.1007/s11255-017-1782-9</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0301-1623 |
| ispartof | International urology and nephrology, 2018-02, Vol.50 (2), p.247-255 |
| issn | 0301-1623 1573-2584 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1982840810 |
| source | SpringerLink Journals |
| subjects | Antitumor activity Apoptosis Cell proliferation Drug discovery Gene expression Kidney cancer Medicine Medicine & Public Health Nephrology Polyethylene oxide Propylene oxide Renal cell carcinoma Urology Urology - Original Paper |
| title | Anticancer activity of Schiff base–Poloxamer P85 combination against kidney cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T11%3A56%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anticancer%20activity%20of%20Schiff%20base%E2%80%93Poloxamer%20P85%20combination%20against%20kidney%20cancer&rft.jtitle=International%20urology%20and%20nephrology&rft.au=Do%C4%9Fan,%20Ay%C5%9Feg%C3%BCl&rft.date=2018-02-01&rft.volume=50&rft.issue=2&rft.spage=247&rft.epage=255&rft.pages=247-255&rft.issn=0301-1623&rft.eissn=1573-2584&rft_id=info:doi/10.1007/s11255-017-1782-9&rft_dat=%3Cproquest_cross%3E1981999934%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1981999934&rft_id=info:pmid/29288416&rfr_iscdi=true |